The treatment of hemophilia has been moving toward longer periods between the dosing of recombinant factors. Now, with the advent of gene therapies, the potential of a one-time curative treatment appears to be on the horizon. But Catalyst Biosciences believes it can improve care for patients with the rare bleeding disorder with a daily self-injection. We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
Stay Connected
Sign up for updates straight to your inbox.